Alfrede Mann News Today

The billionaire media mogul has been intentional with his purchases, buying up land with ties to the history of slavery and racial injustice in order to reclaim the spaces

MNKD earnings call for the period ending September 30, 2023.

Operator: Good afternoon and welcome to the MannKind Corporation 2023 Third Quarter Financial Results Earnings Call.

/PRNewswire/ -- The Alfred E. Mann Foundation for Scientific Research (AMF), a leading nonprofit medical research organization with a nearly 40-year history of...

StockNews.com started coverage on shares of MannKind (NASDAQ:MNKD – Free Report) in a report issued on Thursday morning. The firm issued a hold rating on the biopharmaceutical company’s stock. Other analysts have also recently issued research reports about the stock. Cantor Fitzgerald boosted their price target on shares of MannKind from $6.50 to $7.50 and […]

MannKind (NASDAQ:MNKD – Get Free Report) had its price target upped by investment analysts at Cantor Fitzgerald from $6.50 to $7.50 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price indicates a potential upside of 41.78% from […]

MannKind (NASDAQ:MNKD – Get Free Report) had its target price upped by equities research analysts at Cantor Fitzgerald from $6.50 to $7.50 in a note issued to investors on Tuesday, Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target suggests a potential upside of 41.78% from […]

Shares of MannKind Co. (NASDAQ:MNKD – Get Free Report) hit a new 52-week high on Wednesday after Cantor Fitzgerald raised their price target on the stock from $6.50 to $7.50. Cantor Fitzgerald currently has an overweight rating on the stock. MannKind traded as high as $5.75 and last traded at $5.64, with a volume of […]

MannKind (NASDAQ:MNKD – Get Free Report) and Greenwich LifeSciences (NASDAQ:GLSI – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings. Valuation & Earnings This table compares MannKind and […]

Raymond James & Associates grew its holdings in MannKind Co. (NASDAQ:MNKD – Get Rating) by 80.7% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 619,267 shares of the biopharmaceutical company’s stock after acquiring an additional 276,588 shares during the period. Raymond James & Associates’ holdings in MannKind were worth $3,264,000 at the end […]